C
Callio Therapeutics
Biotechnology firm advancing multi-payload ADCs for targeted cancer therapy with innovative HER2 solutions
About Callio Therapeutics
Callio Therapeutics is a biotechnology company headquartered in Seattle and Singapore, dedicated to advancing cancer therapy through the development of next-generation, multi-payload antibody drug conjugates (ADCs). The company focuses on creating ADCs with differentiated payload and linker technologies, enabling the targeted delivery of drug combinations directly to tumor cells. This approach aims to maximize therapeutic benefits for cancer patients. Callio's lead program involves a dual payload HER2 targeted ADC, with plans to achieve clinical proof of concept using funds from a $187 million Series A financing round. The company serves the oncology market, targeting healthcare providers and institutions involved in cancer treatment. Callio's business model revolves around developing and commercializing its ADC platform, generating revenue through partnerships, licensing agreements, and potential acquisitions. The company is led by Adam Simpson, an experienced executive with a background in life sciences and company creation. Keywords: biotechnology, antibody drug conjugates, cancer therapy, HER2, oncology, targeted delivery, tumor cells, clinical proof, financing, Seattle
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2025
- Headquarters
- Seattle, United States
- Employees
- 19
- Open positions
- None listed
- Dealroom signal
- 93.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Drug Development, Rumoured $1B, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Mar 2025 | $187M | $748M | Norwest Venture Partners · Omega Funds · Seeds Capital · Platanus Ventures | ↗ |
Growth signals
Latest recorded traffic for Callio Therapeutics is 3K monthly website visits, up 11.1% over the last three months. Callio Therapeutics's team grew 18.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A10 investors entered at this stage
Frazier Life Sciences
Norwest Venture Partners
Omega Funds
Seeds Capital
Platanus Ventures
ClavystBio
EDBI
Novo Holdings
Pureos Bioventures
Jeito Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Callio Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Callio Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.